7 results about "Multiple drug resistance" patented technology

The utility model discloses a multi-bin paper-based micro-fluidic chip for visual detection of bacterial drug resistance. The multi-bin paper-based micro-fluidic chip comprises a hydrophilic paper base, the detection mechanism is a hydrophilic channel established on the hydrophilic paper base; the detection mechanism comprises a sample adding bin and an anti-overflow bin, and the appearance of the anti-overflow bin is circular; one end of the anti-overflow channel is communicated with the sample adding bin, and the other end of the anti-overflow channel is communicated with the anti-overflow bin; the appearance of each reaction bin is an isosceles trapezoid; the plurality of reaction bins are uniformly distributed in a fan shape by taking the circle center of the sample adding bin as a central original point; one end of each diffusion channel is communicated with the reaction bin, and the other end of each diffusion channel is communicated with the sample adding bin; wherein the diffusion channels and the reaction bins are arranged in a one-to-one correspondence manner; the hydrophobic barrier structure is a hydrophobic area formed on the hydrophilic paper base through wax spraying printing along the outer edge of the detection mechanism. According to the multi-bin paper-based micro-fluidic chip for visual detection of bacterial drug resistance, provided by the utility model, rapid, high-throughput and low-cost detection of multiple bacterial drug resistance can be realized.

The application discloses application of antibacterial peptide BMAP-28 and antibiotics in combined preparation of antibacterial drugs and belongs to the technical field of biological medicine. The antibiotics are selected from one or more of the following: ciprofloxacin, gentamicin and cefixime. The application combines the antibacterial peptide BMAP-28 with antibiotics such as ciprofloxacin and gentamicin, finds that the combination has a significant synergistic antibacterial effect on Enterobacter sakazii, can greatly save the dosage of the drug, reduce the toxic side effect and block the evolution process of drug resistance. Through the destruction of the bacterial cell membrane and the assistance of the antibiotic effect, the combination can effectively overcome the multiple drug resistance, widen the antibacterial spectrum and has a wide clinical application prospect.

The application discloses K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, hybridoma cell strains thereof and application of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, sequence information of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies is shown as SEQ NO:1-SEQ NO:56, preservation numbers of the hybridoma cell strains are CCTCC:C2023365, CCTCC:C2023366, CCTCC:C2023367, CCTCC:C2024340, CCTCC:C2024341, CCTCC:C2024342 and CCTCC:C2024343 respectively, the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, are favorable for typing of Klebsiella pneumoniae in clinic, and can prove excellent effects of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies in preventing and treating infection of Klebsiella pneumoniae in in-vivo and in-vitro tests, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating Klebsiella pneumoniae infection, and has important value for developing a new generation of Klebsiella pneumoniae drugs.

This invention belongs to the field of biodetection technology, specifically disclosing a primer-probe composition and kit for detecting drug-resistant gene mutations in Helicobacter pylori. The composition comprises two sets of primers and probes, using the probe melting curve method as its principle. The composition and universal PCR reagents are used to detect multiple drug resistance mutations in the quinolone resistance gene gyrA and the clarithromycin resistance gene 23S rRNA of Helicobacter pylori in biological samples. This overcomes the limitation of existing methods that only detect single mutation sites in a single tube for Helicobacter pylori drug resistance genes, providing a new, rapid, and efficient method for detecting Helicobacter pylori drug resistance genes.

The application provides a multifunctional nano drug delivery system based on iron-doped MOF and a preparation method and application thereof. The system comprises: an Fe / MOF core loaded with a chemotherapeutic drug and an HO-1 inhibitor; a PDA coating layer coated on the surface of the Fe / MOF core for providing near-infrared light heat conversion capability and surface modification interface; and E3 aptamer covalently coupled on the PDA coating layer, constituting a synergistic nano platform with active targeting, pH / NIR dual-responsive drug release, chemical kinetics therapy, ferroptosis sensitization, photothermal therapy and immune regulation functions. The nano system can realize efficient accumulation at the tumor site through active targeting mediated by E3 aptamer, and controllably release drugs under an acidic microenvironment or near-infrared light. A new strategy for multi-mechanism synergistic treatment is provided to overcome the multiple drug resistance and immunosuppression of mCRPC, and has important clinical application prospects.

The present application relates to the technical field of biological medicine, in particular to an antifungal drug composition based on (1,3)-beta-D-glucan synthase inhibitor and application thereof. In vivo and in vitro experiments prove that the combination of endogenous antibacterial peptide LL-37 and (1,3)-beta-D-glucan synthase inhibitor (such as caspofungin, micafungin, anidulafungin, rezafungin and albaconazole) shows significant synergistic inhibitory effect on multiple drug-resistant pathogenic fungi such as Candida albicans and Candida auris. Since free antibacterial peptides are easily degraded by proteases, the present application is based on the synergistic killing mechanism of breaking the network barrier of fungal cell wall and assisting endogenous defense peptide to target cell membrane, and ingeniously uses the "antibacterial peptide LL-37 expression promoter" to actively up-regulate the synthesis of host natural peptides, which provides a new drug regimen for clinical treatment of deep fungal infection.

The application discloses a gene and drug resistance mutation detection method based on a double-site nucleic acid circuit probe and belongs to the technical field of molecular biology. In order to solve the technical problems of false positive detection results, complex operation, high requirements for detection personnel and high cost in the prior art gene and drug resistance mutation detection method, the application provides a gene and drug resistance mutation detection method based on a double-site nucleic acid circuit probe. The method is based on isothermal amplification technology combined with one or more nucleic acid circuits. The isothermal amplification technology includes but is not limited to NASBA, SDA, LAMP, HDA and RPA. The nucleic acid circuit includes but is not limited to a cascade strand displacement nucleic acid circuit and a one-step strand displacement nucleic acid circuit. The detection method provided by the application can simultaneously detect multiple drug resistance mutation sites through a single tube and a single reaction, realizes pathogen detection and pathogen drug resistance mutation detection on unknown samples, has high detection accuracy, is simple in steps and low in cost.